Skip to main content
. 2018 Jul 26;119(4):440–449. doi: 10.1038/s41416-018-0188-5

Fig. 3.

Fig. 3

STING agonist treatment enhances a TH1 type response in TME. NanoString-based tumour immune transcriptome profiling showing a significantly differentially expressed immune response, b IFN pathway, and c antigen processing and presentation pathway associated genes in ID8-Trp53−/− tumours collected at endpoint from STING agonist (i.p.) and vehicle-treated mice (n = 3 each group)